The FDA has placed clinical holds on a pair of investigational gene therapies developed to address two rare neurodevelopmental disorders in children, according to the manufacturer. In a press release, ...
REGENXBIO shares sink after the FDA places a clinical hold on two gene therapy trials following a safety concern tied to ...
An AAV vector genome integration event associated with PLAG1 overexpression was identified in a preliminary analysis of the resected tumor.
A central nervous system (CNS) tumor has prompted the FDA to place clinical holds on two Regenxbio gene therapies, including ...
Stocktwits on MSN
RGNX shares pare losses as Wall Street dismisses gene therapy clinical hold spurred selloff as an overreaction
Leerink said the premarket selloff in shares underscores the degree of surprise on the news, feeding into the "FDA ...
Treatment for stage 2 essential thrombocythemia is highly personalized. Not every patient requires medication right away, and ...
Pancreatic schwannoma is usually a benign neoplasm presenting with non-specific symptoms, and preoperative diagnosis is often difficult to establish. The imaging features can overlap from benign ...
Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and daratumumab, a CD38-directed monoclonal antibody, were 83% ...
Researchers from The University of Texas MD Anderson Cancer Center presented promising new data from two ongoing studies of pivekimab sunirine (PVEK), an antibody-drug conjugate targeting CD123, in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results